NewsCagriSema Awaits an FDA Decision. Here Is What the Trials Show, and What Only Novo Has Said
Novo expects an FDA decision on CagriSema in Q4 2026. What is published, what only Novo has reported, and why the tirzepatide comparison is not simple.
CagrilintideInvestigational
SemaglutideFDA-approvedCompounded versions: not FDA-approved
